Lipid-lowering: can ezetimibe help close the treatment gap?
Most patients who should be on lipid-lowering therapy are not receiving it, and most patients who are receiving it are not reaching their appropriate low-density lipoprotein (LDL) goals. This is in part because physicians and patients fear side effects of statins and other lipid-lowering agents. Ezetimibe (Zetia), a new lipid-lowering drug, may help physicians close this "treatment gap" in more patients, especially in combination with a statin.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001384:Azetidines / Q000191:economics / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003327:Coronary Disease / Q000097:blood / Q000517:prevention & control; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood; D012306:Risk
D000924:Anticholesteremic Agents; D001384:Azetidines; D008077:Lipoproteins, LDL; D000069438:Ezetimibe